PLK1 and neoplasm: Research has been shown that cancer cells with KRAS mutation are more sensitive to PLK1 inhibitors than KRAS wild-type cancers [32], suggesting that KRAS mutation induces mitotic stress in tumor cells and may underlie tumor sensitivity to anti-mitotic agents.